CORT Q4 2025: 37% Tablet Volume Gain Reveals Cushing Franchise Demand Surge

2026-02-24 | By EarningsIQ Research

CourseUp Therapeutics’ (CORT) Q4 2025 call spotlighted a decisive inflection in Cushing syndrome franchise demand, with a 37% jump in tablets delivered and 61% new prescription growth, exposing both operational bottlenecks and downstream market opportunity. The FDA’s surprise rejection of relacorlin in Cushing syndrome and the pivotal Rosella trial’s 35% survival risk reduction in ovarian cancer set the stage for a high-stakes 2026, as management juggles regulatory strategy, commercial execution, and a rapidly expanding TAM. Investors face a year of binary catalysts, with pipeline data, pharmacy transition, and patent litigation all reshaping the risk-reward profile.

Summary

• Unmet Demand Unlocked: Cushing syndrome product uptake outpaced operational capacity, revealing latent market size.
• Pipeline Data Catalysts: Positive Rosella and upcoming Momentum results set up new indications and standards of care.
• Regulatory Uncertainty Looms: FDA’s relacorlin rejection and patent litigation inject volatility into 2026 trajectory.

Performance Analysis

CourseUp’s Cushing syndrome franchise delivered a 37% increase in tablets sold and a 61% spike in new prescriptions, underscoring surging demand but also revealing supply chain friction as specialty pharmacy capacity lagged. Leadership attributed the volume gap to the transition between pharmacy vendors, which disrupted operations through January, but now reports that capacity constraints are resolved and monthly new patient starts are on track to reach record levels in February.

Financially, the company’s $761 million in annual revenue reflects this operational lift, though net income compressed year-over-year to $99.7 million, partially due to a $245 million share buyback and ongoing investment in pipeline programs. Notably, the shift toward AG (authorized generic) prescriptions now comprises 78% of volume, pressuring net price but stabilizing as the generic transition matures. Oncology revenue is not yet material to guidance, but the positive Rosella trial results in platinum-resistant ovarian cancer provide a near-term launch catalyst.

• Supply Chain Disruption: Pharmacy vendor transition capped realized sales despite high prescription growth.
• Generic Mix Impact: AG volume reached 78%, stabilizing price erosion but lowering average net price.
• Oncology Ramp Pending: Rosella data positions relacorlin for rapid adoption, but revenue impact awaits FDA approval.

With pharmacy bottlenecks resolved and demand drivers validated by recent trials, the Cushing franchise is positioned for robust organic growth, while regulatory and competitive headwinds remain the key swing factors for 2026.

Executive Commentary

Strategic Positioning

1. Cushing Franchise Momentum

The company’s core business is the treatment of hypercortisolism, primarily through branded and authorized generic (AG) therapies for Cushing syndrome. Recent clinical evidence, particularly from the CATALYST trial, has expanded the addressable patient pool by demonstrating that hypercortisolism is prevalent in resistant diabetes and likely other comorbidities. This scientific validation is translating into commercial momentum, as physicians increasingly screen and treat across a broader spectrum, driving new prescription growth.

2. Operational Reset: Pharmacy Channel

Pharmacy vendor capacity proved a limiting factor in 2025, but the completed transition to a specialty pharmacy partner with scalable infrastructure is expected to unlock latent demand and improve fulfillment rates. The new pharmacy’s orphan drug expertise and multi-location footprint are designed to support future volume surges as the Cushing franchise grows.

3. Pipeline and Indication Expansion

Relacorlin, a selective glucocorticoid receptor (GR) antagonist, is at the center of both the Cushing and oncology growth narratives. The FDA’s unexpected rejection for Cushing syndrome introduces a regulatory overhang, but the Rosella trial’s robust efficacy and safety in ovarian cancer positions relacorlin for a potential new standard of care. Additional studies in hypertension (Momentum), MASH, ALS, and combination oncology regimens broaden the future value horizon.

4. Capital Allocation and Shareholder Returns

The $245 million share repurchase signals management’s confidence in long-term value creation, even as net income contracts due to pipeline investment and generic price erosion. Cash reserves remain strong, supporting both business development and R&D commitments.

5. Litigation and Regulatory Strategy

Patent litigation loss to Teva Pharmaceuticals and the FDA’s CRL on relacorlin for Cushing syndrome create near-term uncertainty. Management is appealing both decisions, with an FDA meeting in April to clarify regulatory path and potential resubmission or additional trial requirements.

Key Considerations

The quarter’s results reflect a business at an inflection point, balancing surging demand, operational reset, and regulatory risk. Investors must weigh the durability of Cushing franchise growth against the binary outcomes of ongoing FDA and patent proceedings.

Key Considerations:

• Unrealized Demand: Prescription volume outpaced product delivery, implying pent-up demand as operational friction resolves.
• Generic Headwind Stabilizing: AG mix is now 78%, with further price erosion expected to be modest, reducing future margin volatility.
• Pipeline Read-Through: Rosella’s 35% reduction in risk of death in ovarian cancer sets a high bar for future oncology launches.
• Regulatory Inflection: April FDA meeting will clarify relacorlin’s Cushing path, with outcomes ranging from resubmission to new trial requirements.
• Capital Deployment: Buybacks and R&D spend reflect confidence, but cash burn will rise if additional trials are mandated.

Risks

Regulatory unpredictability remains the central risk, as FDA’s Cushing CRL and the inability to replicate certain agency analyses highlight a disconnect between sponsor and regulator. Patent litigation loss to Teva threatens branded exclusivity, while further generic penetration could erode pricing faster than anticipated. Execution risk persists in scaling pharmacy operations, and pipeline readouts, while promising, are inherently binary.

Forward Outlook

For Q1 2026, CourseUp Therapeutics guided to:

• Continued revenue growth, with annual 2026 revenue expected in the $900 million to $1 billion range
• Minimal oncology revenue contribution in early 2026, with ramp contingent on relacorlin approval

For full-year 2026, management maintained guidance:

• Cushing syndrome franchise remains the primary growth driver, with pharmacy transition completed

Management highlighted several factors that will shape the year:

• April FDA meeting outcome will determine relacorlin’s Cushing syndrome path
• Momentum hypertension trial data and Rosella oncology launch are major catalysts

Takeaways

CourseUp’s business model is pivoting from a single-asset Cushing franchise toward a multi-indication, data-driven growth story, but near-term performance is still dictated by operational execution and regulatory clarity.

• Cushing Demand Outpaces Supply: Pharmacy transition friction masked true demand, but underlying prescription growth signals expanding TAM and future revenue upside.
• Oncology Pipeline Validated: Rosella’s efficacy and safety set up relacorlin for rapid adoption, though commercial inflection awaits approval and market access.
• 2026 Hinges on FDA and Data: April FDA meeting, Momentum trial, and Rosella launch will determine trajectory, with binary risks around regulatory and competitive events.

Conclusion

CourseUp Therapeutics enters 2026 with strong demand signals, operational reset, and a pipeline poised for expansion, but faces a year defined by regulatory decisions and competitive pressures. The balance between Cushing franchise durability and pipeline execution will determine long-term value realization.

Industry Read-Through

CORT’s experience underscores a broader trend in specialty pharma: operational bottlenecks in pharmacy distribution can cap revenue realization even as clinical data expands the market. The rapid transition to generics and the impact on net price is a cautionary signal for other rare disease franchises. The FDA’s surprise CRL, despite positive pivotal data, highlights the increasing unpredictability of regulatory review, especially for complex or multi-endpoint programs. Oncology launches with robust OS data and favorable safety profiles are likely to see rapid uptake, but payer and biomarker hurdles remain. Investors should monitor pharmacy channel capacity, regulatory alignment, and the durability of branded-to-generic transitions across the sector.

CORT Healthcare Biotechnology Specialty Pharma Pipeline Regulatory Oncology Rare Disease